Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Core Points - Dr. Pardeep Nijhawan has acquired beneficial ownership of more than 2% of Edesa Biotech, Inc.'s common shares since the last early warning report filed on November 18, 2022 [1] - The acquisition was triggered by a grant of 3,055 restricted share units (RSUs) on September 3, 2024, as part of his compensation as CEO [2] - Prior to recent transactions, Dr. Nijhawan held 3,775,809 common shares, representing approximately 19.51% on a non-diluted basis and 22.48% on a partially-diluted basis [3] - After the consolidation of shares and recent transactions, he now holds 544,401 common shares, representing approximately 16.76% on a non-diluted basis and 20.06% on a partially-diluted basis, indicating a decrease in ownership percentage [4] - The beneficial ownership percentages are based on 3,247,389 common shares outstanding as of the news release date [5] - Dr. Nijhawan acquired the common shares for investment purposes and may adjust his ownership in the future based on the evaluation of Edesa's business and financial condition [6]